Stay Updated with the Latest Times Guaranty Limited TIMESGTY.BO News in Real Time
Find TIMESGTY.BO news now at Meyka AI. Stay informed with the latest Times Guaranty Limited stocks updates, including price news, market analysis, and expert insights.
Sui USD Surges 15.9% to $0.8508 as RSI Hits 66.9 on Strong Momentum
Sui USD jumped 15.9% to $0.8508 in 24 hours with volume 2.3x average. RSI at 66.9 and ADX at 29.95 signal strong upward momentum.
Dogecoin Jumps 16.1% to $0.0934 as RSI Signals Extreme Overbought
DOGEUSD surged 16.1% to $0.0934 in 24 hours with RSI at 75.78 and volume 2.1x average, signaling an overheated rally.
Fifth Third Backs Payload’s $500M Monthly Payments Platform on August 23
Fifth Third Bank invests in Payload, an embedded payments platform processing $500M monthly. The deal marks Payload’s first outside capital since 2019 and expands payment options across industries.
XRP Surges 19.9% to $1.52 as RSI Hits Extreme Overbought 80
XRP USD jumped 19.9% to $1.5204 in 24 hours with RSI at 80.08, signaling extreme overbought conditions and a strong uptrend.
Ethereum Surges 5.9% to $2,464.69 as RSI Hits Extreme Overbought 84.7
Ethereum USD jumped 5.9% to $2,464.69 in 24 hours with RSI at 84.7, signaling extreme overbought conditions and a potential pullback.
Solana Climbs 8.5% to $95.08 as RSI Hits Extreme Overbought 78.7
Solana USD surged 8.5% to $95.08 in 24 hours with RSI at 78.7, signaling overbought conditions and potential pullback risk.
Zcash Surges 49.2% to $847.56 as RSI Hits Extreme Overbought 77.9
Zcash USD jumped 49.2% to $847.56 in 24 hours with RSI at 77.9 and volume 2.26x average, signaling extreme overbought conditions.
Take-Two Subpoenas Microsoft, Discord Over GTA 6 Leaks; TTWO Slides 0.2%
Take-Two subpoenas Microsoft and Discord to identify GTA 6 leakers. Nine gameplay videos released by CyberLeek group; game launches November 19. TTWO stock down 0.2%.
Moderna and Merck’s Melanoma Vaccine Jumps Stocks on Phase 3 Win
Moderna and Merck’s personalized mRNA cancer vaccine succeeded in Phase 3 melanoma trials, reducing disease recurrence. MRNA jumped 8.9% and MRK rose 2.4% on the announcement.